An interventional study of Direct contact of family members for cascade screening of relevant variants in Long QT Syndrome, Familial Hypercholesterolemia and Ethics, sponsored by University of Maryland, Baltimore. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Long QT Syndrome with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Long QT Syndrome · United States.
Among the 44 studies in Long QT Syndrome with a site in United States, this one is the 3rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 39th registered.
101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.
Browse Long QT Syndrome studies →7 of the 44 studies in Long QT Syndrome with a site in United States are open now. Recruiting first, the newest first:
Thryv Therapeutics, Inc. · Sites in United States
Ages 15+
Washington University School of Medicine · Sites in United States
Ages 18+
Medical College of Wisconsin · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18–50
Peerbridge Health, Inc · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Long QT Syndrome studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 4 · Phase 3 2 · Phase 4 5
First in 1985; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 45 across 46 interventional studies indexed under Long QT Syndrome.
Median enrollment 44 across the 28 interventional studies, 96 across the 16 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 44 have an industry lead sponsor. The 10 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
University of Maryland, Baltimore has 2 studies filed under Long QT Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Long QT Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277582Phase 3Thryv Therapeutics, Inc.Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) | 2027-06-30 |
| NCT04336644Washington University School of MedicineContinuous Versus Intermittent cARdiac Electrical moNitorinG | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Long QT Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.
Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Aim 1:
Aim 1 will assess efficacy of the approaches on uptake of cascade screening. The primary outcome will assess uptake of cascade screening among all first-degree relatives of the probands. We will compare the proportion first-degree relatives who undergo screening out of all eligible relatives in the direct vs indirect arms of the study. Secondary outcomes will asses rate of detection of new cases among all first degree family members. We will have good power to detect a clinically meaningful difference of 15% between he direct and indirect arms of the study.
These cascade screening efficacy endpoints address the question of whether contacting family members for probands improves the uptake of testing among family members.
Aim 2:
Aim 2 will assess patient-centered outcomes in both probands and family members that address how the intervention of direct contact of family members impacts participants' mental, physical, or psychosocial outcomes. For this aim surveys will be given to the probands and family members approximately one week after contact of family members has occurred and at the end of the study. The secondary outcomes associated with this aim include: perceived alignment of ethical principles, anxiety regarding method of contact, perceived pressure to undergo testing (family members only), and knowledge of disease. We will also assess health behaviors such as taking recommended preventative medications (beta-blockers and statins), lifestyle modifications, and seeing health care providers. These outcomes will be assessed by validated and study-created surveys assessed 1-week post implementation and at the end of study.
These patient-centered outcomes assess the extent to which the intervention allows for autonomous decision making and is associated with acceptable psychosocial outcomes.
Aim 3:
Aim 3 will perform qualitative assessments of the intervention to evaluate implementation outcomes in the direct vs indirect arms of the study. We will include interviews among 15 probands randomized to the direct arm, 15 probands randomized to the indirect arm, 15 family members who undergo cascade screening from the direct arm (carriers and non-carriers), 15 family members who undergo cascade screening from the indirect arm (carriers and non-carriers), and 15 family members who decline cascade testing (from direct arm and from indirect arm but informed by a proband, thus allowing us to invite them to participate). We will also interview study staff to understand facilitators and challenges across patient and organizational factors.
Implementation reach, dosage, and fidelity will be based on proportions and means/standard deviations for relevant quantitative variables (e.g., number of genetic counseling visits scheduled and completed). Outreach approach's acceptability, barriers, and facilitators will be based on descriptive analyses using interview data. Data analyses will be based on a codebook, consensus coding and consensus narrative Qualitative interviews will be transcribed verbatim and analyzed using NVivo 11.0. The research team will conduct standard content analysis and systematic comparison of data between the two intervention groups; acceptability, appropriateness, patterns in facilitators/barriers, implementation quality, and early sustainment.
In sum, these interviews will provide more in-depth understanding of the ethical implications of our intervention and evaluation of the implementation process by relevant stakeholders.
Proband Inclusion Criteria:
Proband Exclusion Criteria:
Family Inclusion Criteria:
Family Exclusion Criteria:
Study team contact of family members
Behavioral: Direct contact of family members for cascade screening of relevant variants
Proband initiated contact of family members
Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.
Uptake of cascade screening among all first-degree relatives
Proportion of first-degree relatives who undergo testing/All eligible first-degree relatives
Time frame: Through study completion: approximately 4 years
Number of new cases detected among all first-degree family members
New cases/All eligible first-degree family members
Time frame: Through study completion: approximately 4 years
Perceived alignment of ethical principles questionnaire
Among probands and family members
Time frame: up to 6 months
Anxiety regarding method of contact questionnaire
Among probands and family members
Time frame: up to 6 months
Perceived pressure to undergo testing/share health information questionnaire
Among probands and family members
Time frame: up to 6 months
Knowledge of disease and variant questionnaire
Among probands and family members
Time frame: up to 6 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Oct 2026, 41 months after the start.
Of 15 interventional studies with no phase under Long QT Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 41 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Maryland, Baltimore →